Myelodysplastic syndromes and iron chelation therapy

Emanuele Angelucci, Silvana Anna Maria Urru, Federica Pilo, Alberto Piperno

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Over recent decades we have been fortunate to witness the advent of new technologies and of an expanded knowledge and application of chelation therapies to the benefit of patients with iron overload. However, extrapolation of learnings from thalassemia to the myelodysplastic syndromes (MDS) has resulted in a fragmented and uncoordinated clinical evidence base. We're therefore forced to change our understanding of MDS, looking with other eyes to observational studies that inform us about the relationship between iron and tissue damage in these subjects. The available evidence suggests that iron accumulation is prognostically significant in MDS, but levels of accumulation historically associated with organ damage (based on data generated in the thalassemias) are infrequent. Emerging experimental data have provided some insight into this paradox, as our understanding of iron-induced tissue damage has evolved from a process of progressive bulking of organs through high-volumes iron deposition, to one of 'toxic' damage inflicted through multiple cellular pathways. Damage from iron may, therefore, occur prior to reaching reference thresholds, and similarly, chelation may be of benefit before overt iron overload is seen. In this review, we revisit the scientific and clinical evidence for iron overload in MDS to better characterize the iron overload phenotype in these patients, which differs from the classical transfusional and non-transfusional iron overload syndrome. We hope this will provide a conceptual framework to better understand the complex associations between anemia, iron and clinical outcomes, to accelerate progress in this area.

Original languageEnglish
Article numbere2017021
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume9
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Chelation Therapy
Myelodysplastic Syndromes
Iron Overload
Iron
Thalassemia
Poisons
Observational Studies
Anemia
Learning
Technology
Phenotype

Keywords

  • Cardiac siderosis
  • Chelation therapy
  • Iron overload
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases

Cite this

Myelodysplastic syndromes and iron chelation therapy. / Angelucci, Emanuele; Maria Urru, Silvana Anna; Pilo, Federica; Piperno, Alberto.

In: Mediterranean Journal of Hematology and Infectious Diseases, Vol. 9, No. 1, e2017021, 2017.

Research output: Contribution to journalArticle

Angelucci, Emanuele ; Maria Urru, Silvana Anna ; Pilo, Federica ; Piperno, Alberto. / Myelodysplastic syndromes and iron chelation therapy. In: Mediterranean Journal of Hematology and Infectious Diseases. 2017 ; Vol. 9, No. 1.
@article{da393ace50c24c9f9ca3584b4a7b879a,
title = "Myelodysplastic syndromes and iron chelation therapy",
abstract = "Over recent decades we have been fortunate to witness the advent of new technologies and of an expanded knowledge and application of chelation therapies to the benefit of patients with iron overload. However, extrapolation of learnings from thalassemia to the myelodysplastic syndromes (MDS) has resulted in a fragmented and uncoordinated clinical evidence base. We're therefore forced to change our understanding of MDS, looking with other eyes to observational studies that inform us about the relationship between iron and tissue damage in these subjects. The available evidence suggests that iron accumulation is prognostically significant in MDS, but levels of accumulation historically associated with organ damage (based on data generated in the thalassemias) are infrequent. Emerging experimental data have provided some insight into this paradox, as our understanding of iron-induced tissue damage has evolved from a process of progressive bulking of organs through high-volumes iron deposition, to one of 'toxic' damage inflicted through multiple cellular pathways. Damage from iron may, therefore, occur prior to reaching reference thresholds, and similarly, chelation may be of benefit before overt iron overload is seen. In this review, we revisit the scientific and clinical evidence for iron overload in MDS to better characterize the iron overload phenotype in these patients, which differs from the classical transfusional and non-transfusional iron overload syndrome. We hope this will provide a conceptual framework to better understand the complex associations between anemia, iron and clinical outcomes, to accelerate progress in this area.",
keywords = "Cardiac siderosis, Chelation therapy, Iron overload, Myelodysplastic syndromes",
author = "Emanuele Angelucci and {Maria Urru}, {Silvana Anna} and Federica Pilo and Alberto Piperno",
year = "2017",
doi = "10.4084/mjhid.2017.021",
language = "English",
volume = "9",
journal = "Mediterranean Journal of Hematology and Infectious Diseases",
issn = "2035-3006",
publisher = "Universita Cattolica del Sacro Cuore",
number = "1",

}

TY - JOUR

T1 - Myelodysplastic syndromes and iron chelation therapy

AU - Angelucci, Emanuele

AU - Maria Urru, Silvana Anna

AU - Pilo, Federica

AU - Piperno, Alberto

PY - 2017

Y1 - 2017

N2 - Over recent decades we have been fortunate to witness the advent of new technologies and of an expanded knowledge and application of chelation therapies to the benefit of patients with iron overload. However, extrapolation of learnings from thalassemia to the myelodysplastic syndromes (MDS) has resulted in a fragmented and uncoordinated clinical evidence base. We're therefore forced to change our understanding of MDS, looking with other eyes to observational studies that inform us about the relationship between iron and tissue damage in these subjects. The available evidence suggests that iron accumulation is prognostically significant in MDS, but levels of accumulation historically associated with organ damage (based on data generated in the thalassemias) are infrequent. Emerging experimental data have provided some insight into this paradox, as our understanding of iron-induced tissue damage has evolved from a process of progressive bulking of organs through high-volumes iron deposition, to one of 'toxic' damage inflicted through multiple cellular pathways. Damage from iron may, therefore, occur prior to reaching reference thresholds, and similarly, chelation may be of benefit before overt iron overload is seen. In this review, we revisit the scientific and clinical evidence for iron overload in MDS to better characterize the iron overload phenotype in these patients, which differs from the classical transfusional and non-transfusional iron overload syndrome. We hope this will provide a conceptual framework to better understand the complex associations between anemia, iron and clinical outcomes, to accelerate progress in this area.

AB - Over recent decades we have been fortunate to witness the advent of new technologies and of an expanded knowledge and application of chelation therapies to the benefit of patients with iron overload. However, extrapolation of learnings from thalassemia to the myelodysplastic syndromes (MDS) has resulted in a fragmented and uncoordinated clinical evidence base. We're therefore forced to change our understanding of MDS, looking with other eyes to observational studies that inform us about the relationship between iron and tissue damage in these subjects. The available evidence suggests that iron accumulation is prognostically significant in MDS, but levels of accumulation historically associated with organ damage (based on data generated in the thalassemias) are infrequent. Emerging experimental data have provided some insight into this paradox, as our understanding of iron-induced tissue damage has evolved from a process of progressive bulking of organs through high-volumes iron deposition, to one of 'toxic' damage inflicted through multiple cellular pathways. Damage from iron may, therefore, occur prior to reaching reference thresholds, and similarly, chelation may be of benefit before overt iron overload is seen. In this review, we revisit the scientific and clinical evidence for iron overload in MDS to better characterize the iron overload phenotype in these patients, which differs from the classical transfusional and non-transfusional iron overload syndrome. We hope this will provide a conceptual framework to better understand the complex associations between anemia, iron and clinical outcomes, to accelerate progress in this area.

KW - Cardiac siderosis

KW - Chelation therapy

KW - Iron overload

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=85014666537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014666537&partnerID=8YFLogxK

U2 - 10.4084/mjhid.2017.021

DO - 10.4084/mjhid.2017.021

M3 - Article

VL - 9

JO - Mediterranean Journal of Hematology and Infectious Diseases

JF - Mediterranean Journal of Hematology and Infectious Diseases

SN - 2035-3006

IS - 1

M1 - e2017021

ER -